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Abstract
Aims We aimed to assess the value of GDF-15, a stress-responsive cytokine, in predicting clinical outcomes in patients with 
heart failure (HF) with reduced ejection fraction (HFrEF) and anemia
Methods and results Serum GDF-15 was assessed in 1582 HFrEF and mild-to-moderate anemia patients who where fol-
lowed for 28 months in the Reduction of Events by Darbepoetin alfa in Heart Failure (RED-HF) trial, an overall neutral 
RCT evaluating the effect darbepoetin alfa on clinical outcomes in patients with systolic heart failure and mild-to-moderate 
anemia. Association between baseline and change in GDF-15 during 6 months follow-up and the primary composite outcome 
of all-cause death or HF hospitalization were evaluated in multivariable Cox-models adjusted for conventional clinical and 
biochemical risk factors. The adjusted risk for the primary outcome increased with (i) successive tertiles of baseline GDF-
15 (tertile 3 HR 1.56 [1.23–1.98] p < 0.001) as well as with (ii) a 15% increase in GDF-15 levels over 6 months of follow-
up (HR 1.68 [1.38–2.06] p < 0.001). Addition of change in GDF-15 to the fully adjusted model improved the C-statistics 
(p < 0.001). No interaction between treatment and baseline or change in GDF-15 on outcome was observed. GDF-15 was 
inversely associated with several indices of anemia and correlated positively with ferritin.
Conclusions In patients with HF and anemia, both higher baseline serum GDF-15 levels and an increase in GDF-15 during 
follow-up, were associated with worse clinical outcomes. GDF-15 did not identify subgroups of patients who might benefit 
from correction of anemia but was associated with several indices of anemia and iron status in the HF patients.
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Introduction
Anemia is common in patients with heart failure (HF) 
and is associated with a high incidence of hospitalization 
and death [1–3]. The cause of anemia in patients with HF 
is often unknown, but may be related to iron deficiency 
or an absolute or relative deficiency of, or resistance to, 
erythropoietin as well as fluid retention [2–5]. Anemia in 
HF patients is associated with impaired renal function, 
potentially causing impaired erythropoietin production, 
and patients with HF often have systemic inflammation, 
which may lead to bone marrow suppression [2, 3].
Growth differentiation factor-15 (GDF-15) is a stress-
responsive cytokine that is activated during inflamma-
tion and tissue remodeling The N-terminal propeptide is 
secreted upon proteolytic cleavage of the precursor pro-
tein as a disulfide-linked dimer with a molecular mass 
of ~ 28 kDa [6]. GDF-15 is expressed in cardiac tissue 
in patients with myocardial infarction [7] and in experi-
mental models of pressure overload and cardiac hyper-
trophy, potentially contributing to myocardial remodeling 
[7, 8]. In clinical HF, serum or plasma levels of GDF-15 
are increased and correlate with clinical and biochemical 
markers of disease severity [9]. Furthermore, high levels 
of GDF-15 are reported in patients with HF and anemia, 
correlated with iron status [10]. It has been suggested 
that GDF-15 may influence erythropoiesis by suppress-
ing hepcidin expression, a major regulator of iron status 
[11]. However, the effect of GDF-1 on erythropoiesis is 
still unclear, and the suppressive effects of GDF-15 on 
hepcidin were tested in a very different setting (in vitro 
experiments in hepatocytes) than in HF patients [11]. Sev-
eral studies suggest an association between high GDF-15 
and adverse outcome in HF [12–15]. In the large Valsartan 
Heart Failure Trial (Val-HeFT, n = 1734), baseline GDF-
15 was independently associated with mortality even after 
adjusting for multiple clinical and biochemical prognostic 
variables including BNP, hs-CRP, and hs-Troponin [16].
Personalized medicine is receiving increasing attention 
and there is a need to evaluate how promising biomarkers 
perform in more homogenous populations and to iden-
tify if they can predict a beneficial response to targeted 
therapy. Whereas use of the erythropoiesis-stimulating 
agent Darbepoetin was not associated with improvement 
in clinical outcomes in the overall population in RED-
HF (Reduction of Events by Darbepoetin alfa in Heart 
Failure) trial [17], a benefit of correcting anemia in some 
subgroup of patients cannot be ruled out. Because GDF-15 
is involved in inflammation and remodeling in cardiac and 
extracardiac tissues and may be related to erythropoie-
sis, we hypothesized that plasma concentration of GDF-
15 may provide prognostic information in patients with 
HFrEF and anemia and identify patients who may ben-
efit from darbepoetin alfa treatment. This hypothesis was 
tested in 1582 patients from the RED-HF trial who were 
followed for 28 months and with a primary outcome of the 
composite of death from any cause or first hospitalization 
for worsening of HF.
Materials and methods
Patients and study procedures
The study design and baseline characteristics of the RED-
HF trial have been reported in detail previously [18, 19]. 
Patients were eligible for the study if they had the New York 
Heart Association (NYHA) functional class II–IV; HFrEF 
and left ventricular EF (LVEF) ≤ 40%; a hemoglobin level 
of 9.0–12.0 g per deciliter and were receiving guideline-
recommended HF therapy. Patients were randomly assigned 
in a 1:1 ratio to receive either darbepoetin alfa or placebo. 
The study drug was administered subcutaneously, with doses 
adjusted according to hemoglobin level, which was meas-
ured in a blinded fashion.
Study outcomes and definitions
The primary predefined outcome was a composite of death 
from any cause or first hospitalization for worsening of HF. 
The prespecified adjudicated secondary outcomes were (1) 
composite of death from cardiovascular (CV) causes or first 
hospitalization for worsening of HF, (2) death from any 
cause, and (3) CV death. Details on the definition and adju-
dication of all outcomes, with specific causes of CV death, 
have been described previously [17].
Unresponsiveness to darbepoetin alfa
The hematopoietic response to DA was assessed as the per-
centage change in hemoglobin level between baseline and 
week 5 (after the 2 weight-based doses of DA) as previ-
ously reported [20]. Patients in the lowest quartile did not 
respond at all to DA and were considered non-responders, 
whereas subjects in the upper three quartiles were consid-
ered responders.
Blood sampling and biochemical analyses
At randomization and 6-month follow-up, fasting venous 
blood was collected and serum and plasma were separated 
and stored at − 80 °C until thawing for assay. All blood 
samples were non-fasting and all biomarkers, except for 
GDF-15, were measured at a central laboratory including 
N-terminal pro-brain natriuretic peptide (NT-proBNP), high 
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sensitivity assays for C-reactive protein (hsCRP), troponin 
T (hsTnT), serum iron, transferrin saturation and ferritin 
(measured as light-chain ferritin) (Medical Research Labora-
tories, Zaventem, Belgium). Plasma concentration of GDF-
15 was analyzed by enzyme immunoassays from R&D Sys-
tems (Minneapolis, MN, USA) with intra- and inter-assay 
coefficients of variation < 10%. All samples were thawed an 
equal number of times (< 2 times). The analyses were per-
formed in a 384-format using the combination of a SELMA 
(Jena, Germany) pipetting robot and a BioTek (Winooski, 
VT, USA) dispenser/washer. Absorption was read at 450 nm 
with wavelength correction set to 540 nm using an ELISA 
plate reader (Bio-Rad, Hercules, CA, USA).
Statistical analysis
See Supplemental File for a full description of statistics. 
Kaplan–Meier curves were constructed to visualize and 
evaluate (log rank test) differences in survival. A restricted 
cubic spline analysis with three knots was undertaken on 
the primary outcome to assess linearity of risk. Survival 
analyses were performed using the Cox proportional hazard 
regression models to estimate hazard ratios (HRs) and 95% 
confidence intervals (CIs) for GDF-15 as a log-transformed 
continuous variables at baseline, which included age, gender, 
NYHA class, hospitalization for HF within 6 months, log 
serum creatinine, LVEF, etiology, body mass index (BMI), 
left bundle-branch block, history of atrial fibrillation or 
flutter, systolic blood pressure) at step one, log-transformed 
serum concentrations of NT-proBNP, hsTnT and hsCRP at 
step two. For the analysis of changes in GDF-15 concentra-
tions from baseline to 6-month follow-up, a 15% relative 
change was used as cutoff, which is consistent with other 
studies [21]. Tertile changes were also assessed. A two-sided 
p value < 0.05 was considered to be significant. All statisti-




Of the 2278 patients enrolled in the RED-HF study, 
baseline measurement of GDF-15 was available for 
1582 (69%). The median plasma level of GDF-15 at 
baseline in the overall population was 4170 ng/L (IQR 
2669–6272 ng/L). There were no differences in demo-
graphics comparing participants in the biomarker sub-
study population with the main RED-HF population and 
few differences between the treatment groups except mod-
estly higher NYHA class and platelet count in patients 
receiving Darbepoetin alfa (Supplemental Table  1). 
Table 1 shows the demographic and clinical character-
istics according to tertiles of GDF-15. Elevated GDF-15 
was associated with multiple characteristics indicating 
more severe HF (and worse outcomes) such as higher age, 
male sex, duration of disease, prevalence of diabetes, MI 
during the past 6 months, atrial fibrillation/flutter, poor 
kidney function, higher TnT and NT-proBNP levels and 
relevant for this population, lower iron, hemoglobin and 
transferrin saturation. As shown in Supplemental Table 2, 
stepwise linear regression identified lower hemoglobin as 
an independent predictor of GDF-15.
Association of baseline GDF‑15 levels and outcomes
During a mean follow-up of 28  months (range 
0.03–72.4 months), 798 patients reached a primary end-
point, 716 patients reached the secondary endpoints, while 
649 patients died and of these, 543 due to CV causes. 
Cubic spline analysis revealed an increase in risk of the 
primary endpoint with increasing GDF-15 (Fig. 1A) and 
this was mirrored by the Kaplan–Meier analysis (Fig. 1B) 
indicating a stepwise increase in the risk for the primary 
outcome with increasing tertiles (3rd tertile HR 4.05 
[3.25–4.90]) relative to the lowest tertile in cox regres-
sion (adjusted for randomization) with a similar pattern 
for the other endpoints (Table 2). In multivariable analysis 
adjusting for pre-specified clinical variables (as outlined 
in statistical methods), the association between GDF-15 
and outcome, evaluated according to tertiles and as a con-
tinuous variable, while attenuated, remained significantly 
associated with all end points with HR’s ranging from 
2.47 to 2.62 for tertile 3 (all p < 0.001) (Step 1, Table 2). 
Addition of NT-proBNP, TnT and CRP to the multivari-
able models, attenuated the predictive value of GDF-15, 
but it remained significantly associated with all outcomes 
with HRs around 1.5 (Step 2, Table 2). Adding GDF-15 to 
the fully adjusted model did not improve the C-statistics; 
however, a significant effect on NRI was observed for all 
endpoints except cardiovascular mortality (Table 2).
Comparison of the prognostic value of GDF‑15 
with NT‑proBNP and hs‑TnT
As shown in Supplemental Figure 1, GDF-15, NT-proBNP 
and TnT all contribute to a model without any other bio-
marker, with the biggest gain by NT-proBNP followed by 
TnT and GDF-15. Similarly, the largest decrease in c sta-
tistic was seen when NT-proBNP is subtracted from the 
full model including all biomarkers. For all-cause mortal-
ity, all markers contribute to a similar degree.
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Association of change in GDF‑15 levels 
and outcomes
An increase in serum GDF-15 of > 15% during follow-up 
was associated with a higher incidence of the primary out-
come following the second sampling (Table 3) adjusting 
for randomization (HR 1.39 [1.15–1.69] p < 0.002) and 
multivariable (HR 1.68 [1.38–2.06] p < 0.001) analyses 
with a similar pattern for the secondary composite and 
mortality outcomes (HR’s of 1.40–1.73 after full adjust-
ment (Table 3). Furthermore, adding change in GDF-15 
to the fully adjusted model improved the C-statistics (all 
p < 0.004) and a significant effect on NRI (all p < 0.001) 
was observed for all endpoints (Table 3).
Supplemental Table 3 shows the association between 
change in GDF-15 and outcomes evaluated as tertiles. This 
analysis supports that those with the largest increase in 
GFD-15 (T3) had a higher incidence of all outcome meas-
ures. The mid tertile (T2) displayed a lower risk compared 
to the lower tertile. Baseline GDF-15 levels were strongly 
correlated with levels at 6 months (r = 0.83, p < 0.001), 
but negatively correlated with change scores (r = − 0.23, 
p < 0.001). Finally, we made a heatmap of the incidence 
Table 1  Baseline characteristics 
of the patients by GDF-15 
tertiles
Patient characteristics are given as mean ± SD for continuous variables and % of cases for categorical vari-
ables
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker, BMI body mass index, BP blood 
pressure, eGFR estimated glomerular filtration rate, hsCRP high-sensitivity C-reactive protein, hsTnT high-
sensitive troponin
Characteristic T1, n = 529 T2, n = 526 T3, n = 527 p value
GDF-15 range (ng/L) (500–3121) (3122–5394) (5399–20,480)
Age, yrs 65 ± 13 71 ± 11 73 ± 10  < 0.001
Female sex 64 39 28  < 0.001
Race (white/black) 59/14 68/8 72/7  < 0.001
BMI (SD) kg/m2 27.6 ± 5.9 27.2 ± 5.7 26.4 ± 5.5  < 0.001
NYHA (III or IV) 64 67 68 0.304
Ischemic HF 60 75 80  < 0.001
Duration HF, yrs 5.0 ± 5.1 5.3 ± 5.4 5.8 ± 5.7 0.012
LVEF,% 31.1 ± 6.4 30.2 ± 6.8 29.5 ± 7.3 0.005
Medical history
 Hypertension 74 74 74 0.805
 Diabetes 32 48 54  < 0.001
 Atrial fibrillation or flutter 20 30 45  < 0.001
 MI last 6 mo 28 35 47  < 0.001
Medication
 ACE or ARB 95 91 84  < 0.001
 Beta-blocker 85 86 85 0.980
 Diuretic 87 91 96  < 0.001
Systolic BP 123 ± 17 120 ± 18 117 ± 19  < 0.001
Heart rate, b.p.m. 73 ± 11 71 ± 12 73 ± 12 0.044
Biochemistry
 Creatinine, mg/dL 1.1 ± 0.4 1.5 ± 0.5 1.8 ± 0.6  < 0.001
 eGFR, mL/min/1.73m2 64 ± 22 48 ± 19 39 ± 16  < 0.001
 Hemoglobin, g/dL 11.2 ± 0.6 11.0 ± 0.7 10.9 ± 0.7  < 0.001
 Transferrin saturation, % 27.5 ± 10.6 27.1 ± 10.8 26.4 ± 11.2 0.007
 Iron, μg/dL 80.4 ± 34.5 75.7 ± 38.5 74.3 ± 37.3 0.019
 Ferritin, μg/L 116 ± 133 165 ± 174 179 ± 190  < 0.001
 Platelets, ×  109/L 251 ± 80 231 ± 80 212 ± 73  < 0.001
 WBC, ×  109/L 6.5 ± 2.1 6.9 ± 2.2 6.7 ± 2.2 0.143
 hsCRP, mg/dL 2.4 (1.1,5.4) 2.7 (1.1,7.2) 3.0 (1.3,7.2)  < 0.001
 NT-proBNP, pmol/L 994 (220,2334) 1823 (762,3820) 2983 (1196,7002)  < 0.001
 hsTnT, ng/ml 12 (9,17) 28 (21,34) 46 (33,71)  < 0.001
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of the primary outcome according to quartiles of baseline 
and change in GDF-15. As shown in Fig. 2, the incidence 
was highest among all quartiles of change for quartile 4 of 
baseline GDF-15 with the highest incidence for quartile 
4 of both baseline and change values. However, a mark-
edly higher incidence for change in quartiles 3 and 4 vs. 
1 and 2 was noted within quartile 1 of baseline GDF-15 
(i.e. ~ 28% vs. ~ 20%).
GDF‑15 and iron metabolism
To understand the potential role of GDF-15 in iron 
metabolism and erythropoiesis, we further analyzed asso-
ciations between GDF-15 and different markers related to 
iron metabolism. As shown in supplemental Table 4 and 
Fig. 3A, at baseline GDF-15 was inversely correlated with 
hemoglobin and positively with ferritin, with weaker posi-
tive associations with transferrin saturation and iron. In the 
Fig. 1  Association between 
baseline GDF-15 levels and 
the primary endpoint in the 
RED-HF cohort (n = 1582) 
during the whole study (mean 
follow-up 28 months, range 
0.03–72.4 months) expressed as 
A restricted cubic spline with 
tertile cut-offs at enrollment 
shown as dotted lines and B 
Kaplan–Meier curves showing 
the cumulative incidence of the 
primary endpoint according to 
tertiles at enrollment
Table 2  Association of baseline GDF-15 with outcomes
Hazard ratios and 95% confidence interval are shown for tertile 2 and 3 and for GDF-15 as a continuous (log) variable in univariate (UNI) analy-
sis, when adjusted for clinical and biochemical variables (Step 1), and last for CRP, TnT and NT-proBNP (Step 2)
*Comparing the fully adjusted models with and without inclusion of log GDF15
Univariable Step 1 Step 2 Δ C-index (p value)* NRI (p value)*
All-cause mortality or first hospitalization for worsening heart failure, n = 798
 T2 2.10 (1.72‒2.57) 1.63 (1.32‒2.01) 1.20 (0.96‒1.49)
 T3 4.05 (3.35‒4.9) 2.57 (2.05‒3.23) 1.56 (1.23‒1.98)
 Continuous 2.29 (2.06‒2.54) 1.80 (1.58‒2.04) 1.26 (1.10‒1.45)
 p-trend/p-cont*  < 0.001/< 0.001  < 0.001/< 0.001  < 0.001/0.001 0.003 (0.148) 0.183 (< 0.001)
Cardiovascular mortality or first hospitalization for worsening heart failure, n = 716
 T2 2.10 (1.71‒2.59) 1.62 (1.30‒2.02) 1.20 (0.95‒1.50)
 T3 3.94 (3.22‒4.81) 2.47 (1.94‒3.13) 1.56 (1.23‒1.99)
 Continuous 2.25 (2.01‒2.51) 1.74 (1.52‒1.98) 1.22 (1.05‒1.41)
 p-trend/p-cont*  < 0.001/< 0.001  < 0.001/< 0.001 0.004/0.010 0.002 (0.212) 0.150 (0.003)
All-cause mortality, n = 649
 T2 2.22 (1.77‒2.78) 1.75 (1.39‒2.22) 1.32 (1.03‒1.68)
 T3 3.93 (3.17‒4.88) 2.62 (2.03‒3.38) 1.64 (1.25‒2.14)
 Continuous 2.32 (2.05‒2.59) 1.89 (1.64‒2.18) 1.37 (1.17‒1.60)
 p-trend/p-cont*  < 0.001/< 0.001  < 0.001/< 0.001 0.001/< 0.001 0.005 (0.108) 0.166 (0.001)
Cardiovascular mortality, n = 543
 T2 2.31 (1.81‒2.94) 1.82 (1.40‒2.35) 1.35 (1.04‒1.77)
 T3 3.75 (2.96‒4.74) 2.47 (1.86‒3.26) 1.50 (1.11‒2.01)
 Continuous 2.24 (1.97‒2.55) 1.82 (1.56‒2.13) 1.29 (1.08‒1.53)
 p-trend/p-cont  < 0.001/< 0.001  < 0.001/< 0.001 0.026/0.005 0.003 (0.220) 0.099 (0.061)
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population as a whole, change in GDF-15 did not correlate 
with the iron parameters. At 6 months’ follow-up, somewhat 
stronger associations between GDF-15 and markers of iron 
metabolism were observed, with no significant differences 
according to treatment group.
Interactions between iron deficiency markers, 
GDF‑15 and outcomes
We next analyzed interactions between GDF-15 and iron 
status on outcome by dividing the iron status markers in 
tertiles and evaluating the prognostic role of GDF-15 (con-
tinuous log transformed) within each tertile. These data 
are presented adjusted for randomized treatment and after 
full multivariable adjustment in Supplemental Table 5 and 
graphically in Fig. 3B. The association between GDF15 and 
the primary outcome was not dependent on iron levels, while 
a stronger association was observed with increasing ferritin 
and transferrin saturation. Conversely, lower and mid-tertile 
levels of hemoglobin were associated with adverse outcomes 
with increasing GDF-15. These associations were quite 
similar for the secondary endpoints, but low or intermedi-
ate levels of iron were more strongly associated with worse 
outcome for the mortality endpoints (Supplemental Table 5).
Effect of darbepoetin on GDF‑15
Plasma GDF-15 levels were similar at baseline in the 
two treatment groups (mean ± SD 4866 ± 3123  ng/L vs. 
4781 ± 3077  ng/L (p = 0.79), placebo and Darbepoetin, 
respectively. During the course of the study, a small decrease 
in GDF-15 was observed in the Darbepoetin group (p = 0.032, 
Fig. 3C), but not in the placebo group, yielding a modest but 
significant difference in relative change between the treatment 
Table 3  Association of change in GDF-15 with outcomes
Hazard ratios and 95% confidence interval are shown for ≤ − 15% and > 15% change vs. no change (− 15‒15%) in univariate (UNI) analysis, 
when adjusted for clinical and biochemical variables (Step 1), and last for CRP, TnT and NT-proBNP (Step 2)
*Comparing the fully adjusted models with and without inclusion of log GDF15
Univariable Step 1 Step 2 Δ C-index (p value)* NRI (p value)*
All-cause mortality or first hospitalization for worsening heart failure
  ≤ − 15% 1.06 (0.86‒1.29) 0.95 (0.77‒1.17) 0.98 (0.80‒1.21)
  > 15% 1.39 (1.15‒1.69) 1.65 (1.36‒2.01) 1.68 (1.38‒2.06)
 p-trend 0.002  < 0.001  < 0.001 0.050 (< 0.001) 0.266 (< 0.001)
Cardiovascular mortality or first hospitalization for worsening heart failure
  ≤ − 15% 1.09 (0.88‒1.35) 0.97 (0.78‒1.20) 1.00 (0.80‒1.25)
  > 15% 1.46 (1.19‒1.80) 1.72 (1.40‒2.11) 1.73 (1.40‒2.14)
 p-trend 0.001  < 0.001  < 0.001 0.051 (< 0.001) 0.228 (< 0.001)
All-cause mortality
  ≤ − 15% 1.00 (0.80‒1.25) 0.98 (0.78‒1.24) 1.02 (0.81‒1.29)
  > 15% 1.23 (0.99‒1.53) 1.47 (1.18‒1.83) 1.40 (1.12‒1.76)
 p-trend 0.118 0.001 0.007 0.038 (0.004) 0.219 (< 0.001)
Cardiovascular mortality
  ≤ − 15% 1.05 (0.82‒1.35) 1.03 (0.80‒1.33) 1.08 (0.84‒1.39)
  > 15% 1.35 (1.07‒1.71) 1.59 (1.25‒2.03) 1.49 (1.16‒1.91)
 p-trend 0.037  < 0.001 0.005 0.047 (0.002) 0.222 (< 0.001)
Fig. 2  Heatmap showing 
association between baseline 
GDF-15 and change in GDF-15 
on incidence (%) of the primary 
outcome. Both baseline (ng/mL) 
and change (%) are shown as 
quartiles with limits
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groups (mean change 0.0 vs. 0.1 p = 0.039, placebo and Dar-
bepoetin, respectively).
Interactions between darbepoetin alpha treatment 
and GDF‑15 and outcomes
We next evaluated whether baseline levels or change in GDF-
15 could identify patients who could benefit from Darbepoetin 
treatment. We found no evidence for this for baseline GDF-
15, with interaction p values for treatment*GDF-15 (tertiles) 
between 0.55 and 0.83 in unadjusted analysis for the differ-
ent outcomes. A similar pattern was seen for change in GDF-
15 (as categorized above) with interaction p values ranging 
between 0.11 and 0.82.
GDF‑15 and unresponsiveness to darbepoetin in HF 
patients
The median initial hemoglobin change in non-responders 
(n = 198) was − 0.25 g/dL and + 1.00 g/dL in the remainder 
of patients (n = 592). ROC analysis indicated no associa-
tion between GDF-15 levels and unresponsiveness to ESA 
(AUC = 0.51). Evaluated as a continuous variable, GDF-15 
did not identify non-responders: HR 0.99 (0.81–1.18) and 
the HRs were unmodified by the addition of markers of iron 
metabolism to the model (i.e. ferritin, hemoglobin, trans-
ferrin saturation, iron). Similar results were obtained when 
GDF-15 was evaluated according to tertiles:tertile 2 HR 0.86 
(95% CI: 0.54–1.35); tertile 3 HR 0.85 (0.53–1.34). These 
Fig. 3  Association between GDF-15 and iron status in HF patients. 
A Correlation between GDF-15 and iron status markers at baseline 
and 1  year and change between these time-points. B Association 
between GDF-15 and the primary endpoint (death from any cause or 
first hospitalization for worsening of HF), secondary endpoint (death 
from cardiovascular causes or first hospitalization for worsening of 
HF), death and CV death within tertiles of iron status markers. The 
fully adjusted hazard ratio (HR) and 95% CI are shown. C Effect of 
Darbepoetin on GDF-15 levels in HF patients. *p < 0.05, **p < 0.01, 
*** < 0.001
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HRs were unmodified by the addition of markers of iron 
metabolism to the model.
Discussion
In our study, higher baseline GDF-15 levels or an increase in 
GDF-15 levels during follow-up were associated with poor 
prognosis in adjusted analysis including TnT, CRP and NT-
proBNP, all strong predictors of outcome in HF patients [22, 
23]. Furthermore, change in GDF-15 improved the discrimi-
nation and the magnitude of net improvement in sensitivity 
and specificity when added to these models. GDF-15 was 
associated with all iron status markers with the strongest 
correlation with hemoglobin but could not identify unre-
sponsiveness or responsiveness to Darbepoetin. Our findings 
further support a role for GDF-15 as a strong and independ-
ent prognostic marker in patients with HF.
GDF-15 has been reported to add prognostic informa-
tion in several CV disorders including myocardial infarc-
tion (MI), atherosclerosis, aortic stenosis, pulmonary hyper-
tension and ischemic stroke [6, 24] as well as in HFrEF 
[12–16, 25] and more recently also in HF with preserved 
EF (HFpEF) [13, 15, 25]. However, like several other inflam-
matory markers, GDF-15 is not specific for HF or other CV 
disorders and is not useful as a diagnostic tool, although 
capable of giving prognostic information as we have shown. 
Kempf et al. showed that in 455 patients with systolic HF, 
GDF-15 predicted total mortality independent of biochemi-
cal and clinical variables including NT-proBNP [12]. Chan 
et al. found that in 730 patients with systolic HF, baseline 
GDF-15 was associated with the composite outcome of all-
cause mortality and first re-hospitalization of HF also after 
adjusting for established clinical and biochemical variables 
including TnT and NT-proBNP, with a similar pattern in 
HFpEF [13]. Gaggin et al. found that in 151 patients with 
chronic HF, GDF-15 together with TnT and the soluble ver-
sion of the interleukin 1 receptor member ST2 was inde-
pendently associated with CV events also after adjusting 
for NT-proBNP [14]. In a substudy of Val-HeFT (n = 1734), 
baseline GDF-15 levels were associated with all-cause mor-
tality and the first morbid event after adjusting for clinical 
and biochemical variables [16]; the association remained 
significant for all-cause mortality but not for the first morbid 
event when further adjustments were made for TnT, CRP 
and NT-proBNP. Similar to the Val-HeFT study, we found 
that an increase in GDF-15 was strongly associated with 
poor prognosis, with significant improvement in discrimina-
tion analysis for all outcomes. However, the negative cor-
relation between baseline GDF-15 and change in GDF-15, 
and relatively larger increase in incidence of the primary 
outcome with increasing quartiles of change within quar-
tile 1 of baseline GDF-15, suggests patients with the largest 
increase are not only those presenting with high GDF-15 
levels. Indeed, thus, serial analysis could be beneficial in 
identifying patients not detected by the initial measurement.
The independent association between GDF-15 and 
adverse outcome in chronic HF may have several non-mutu-
ally exclusive explanations. First, GDF-15 is strongly up-
regulated in the myocardium during wall stress and ischemia 
[7, 8], and it is possible that the plasma levels in HFrEF 
at least partly reflect up-regulation of GDF-15 in failing 
myocardium. Second, GDF-15 seems to reflect activation 
of inflammatory, myocardial remodeling and apoptotic path-
ways-, and the ability of a measure like GDF-15 to mirror 
several pathological processes is an important feature of a 
robust biomarker. Notably, GDF-15 exhibits potent anti-
inflammatory, anti-hypertrophic and anti-apoptotic proper-
ties and its up-regulation during HF seems to reflect multiple 
and counteractive mechanisms [7, 8].
While the RED-HF trial failed to detect a benefit of an 
erythropoiesis-stimulating agent on clinical outcomes, this 
does not exclude the possibility that some individuals may 
benefit from correction of anemia. Enhanced hepcidin pro-
duction has been implicated in the pathogenesis of anemia 
in chronic inflammatory disorders like HF [26], and GDF-
15 was recently identified as a hepcidin-suppression factor 
[11]. However, the suppressive effect of GDF-15 on hepcidin 
was not tested in this study and has not been reported in 
HF patients in other studies. Nor has an interaction between 
GDF-15 and erythropoiesis been clarified to our knowledge. 
In the present study, we found mostly weak correlations 
between GDF-15 and markers of iron metabolism. How-
ever, a stronger association between GDF15 and the primary 
outcome was observed with increasing ferritin and transfer-
rin saturation, and conversely, lower and mid-tertile levels 
of hemoglobin were associated with adverse outcomes with 
increasing GDF-15, suggesting some interaction between 
GDF-15 and iron metabolism. Moreover, GDF-15 levels in 
our study population seems to be higher than in previous 
study in HF patients [9]. Although the GDF-15 assay was 
not calibrated against a universal standard, it is possible that 
the additional burden of anemia could have contributed to 
the elevated levels GDF-15 levels in the present study as 
compared to HF patients without anemia as also has been 
suggested by others [10].
Limitations
The strengths of the present investigation include the large 
number of patients studied with a high event rate, longitu-
dinal sampling and adjustment for multiple relevant con-
founders. On the other hand, a randomized trial may not 
necessarily reflect the “real-world” HF population and the 
use of composite endpoints has an inborn limitation. Our 
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patients also had anemia, and our results will, therefore, 
not apply to all chronic HF cohorts. However, anemia is 
common in HF, in particular in advanced cases. Finally, 
the lack of data on hepcidin levels is also a limitation of 
the present study.
Conclusions
Our findings indicate that GDF-15 is a promising prognos-
tic marker in patients with chronic HF and anemia, with 
correlation to indices of iron metabolism. Future studies 
should examine whether this marker could be used for 
treatment-related decision-making and risk stratification 
in these patients.
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